Literature DB >> 26209624

Au-ACRAMTU-PEt3 Alters Redox Balance To Inhibit T Cell Proliferation and Function.

P Kent Langston1, Mu Yang2, Ulrich Bierbach2, Derek Parsonage3, Leslie B Poole3, Madeline J Price1, Jason M Grayson4.   

Abstract

Although T cells play a critical role in protection from viruses, bacteria, and tumors, they also cause autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. Unwanted T cell responses during organ transplant, graft-versus-host disease, and allergies are also major clinical problems. Although drugs are available to suppress unwanted immune responses, they have limited efficacy with serious side effects. Thus, new therapeutics limiting T cell activation, proliferation, and function can make an immediate clinical impact. To identify new suppressors of lymphocyte activation, proliferation, and function, we examined the immunosuppressive activity of gold(I) analogs of platinum-acridine antitumor agents. We found that the gold complex Au-ACRAMTU-PEt3 is a potent suppressor of murine and human T cell activation. Preincubation with Au-ACRAMTU-PEt3 suppresses the proliferation of CD4(+) and CD8(+) T cells at a similar concentration as pharmaceutical grade cyclosporine A. Au-ACRAMTU-PEt3 pretreatment decreases the production of IFN-γ, TNF-α, IL-2, and IL-17 by human and murine CD4(+) and CD8(+) T cells. When mice were treated with Au-ACRAMTU-PEt3 during viral infection, the expansion of virus-specific CD8(+) T cells was decreased 10-fold and viral load was elevated. Taken together, these results demonstrate that Au-ACRAMTU-PEt3 has potent immunosuppressive activity that could be used to suppress immune responses during transplantation and autoimmunity.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26209624      PMCID: PMC4854305          DOI: 10.4049/jimmunol.1400391

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

Review 1.  Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.

Authors:  A C Webster; V W Lee; J R Chapman; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 2.  Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?

Authors:  Jeremy R Chapman; Brian J Nankivell
Journal:  Nephrol Dial Transplant       Date:  2006-05-25       Impact factor: 5.992

3.  Design, synthesis, and biological activity of a novel non-cisplatin-type platinum-acridine pharmacophore.

Authors:  E T Martins; H Baruah; J Kramarczyk; G Saluta; C S Day; G L Kucera; U Bierbach
Journal:  J Med Chem       Date:  2001-12-06       Impact factor: 7.446

Review 4.  Updating on the pathogenesis of systemic lupus erythematosus.

Authors:  R Gualtierotti; M Biggioggero; A E Penatti; P L Meroni
Journal:  Autoimmun Rev       Date:  2010-09-21       Impact factor: 9.754

5.  IL-4 gene expression up-regulated by mercury in rat mast cells: a role of oxidant stress in IL-4 transcription.

Authors:  Z Wu; D R Turner; D B Oliveira
Journal:  Int Immunol       Date:  2001-03       Impact factor: 4.823

Review 6.  Hypertension in kidney transplant recipients.

Authors:  Claudio Ponticelli; David Cucchiari; Giorgio Graziani
Journal:  Transpl Int       Date:  2011-03-08       Impact factor: 3.782

7.  The Erk2 MAPK regulates CD8 T cell proliferation and survival.

Authors:  Warren N D'Souza; Chiung-Fang Chang; April M Fischer; Manqing Li; Stephen M Hedrick
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Gold(I) analogues of a platinum-acridine antitumor agent are only moderately cytotoxic but show potent activity against Mycobacterium tuberculosis.

Authors:  Lauren C Eiter; Nathan W Hall; Cynthia S Day; Gilda Saluta; Gregory L Kucera; Ulrich Bierbach
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

9.  Molecular mechanisms of treg-mediated T cell suppression.

Authors:  Angelika Schmidt; Nina Oberle; Peter H Krammer
Journal:  Front Immunol       Date:  2012-03-21       Impact factor: 7.561

10.  Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function.

Authors:  Julie M Curtsinger; Debra C Lins; Matthew F Mescher
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307

View more
  3 in total

1.  Human Serum Albumin-Delivered [Au(PEt3)]+ Is a Potent Inhibitor of T Cell Proliferation.

Authors:  Tyler C Dean; Mu Yang; Mingyong Liu; Jason M Grayson; Anthony W DeMartino; Cynthia S Day; Jingyun Lee; Cristina M Furdui; Ulrich Bierbach
Journal:  ACS Med Chem Lett       Date:  2017-04-25       Impact factor: 4.345

Review 2.  Autoimmunity in 2015.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

3.  Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.

Authors:  Kathrin Thell; Roland Hellinger; Emine Sahin; Paul Michenthaler; Markus Gold-Binder; Thomas Haider; Mario Kuttke; Zita Liutkevičiūtė; Ulf Göransson; Carsten Gründemann; Gernot Schabbauer; Christian W Gruber
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.